ROARABLE
FREE $100K
My Trading Account →
▾
Trading Profile Active
Active Trader
Verified Trader
⚡ My $100K Trading Account → ★ My Saved Watchlist →
🟢 My $100K Account → Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / CELU / forecast
BYSI (37) BCTX (40) ABVC (32) CPHI (35) ⌘ Pro Terminal →

Celularity Inc. (Class A) (CELU) 12-Month Stock Forecast & Price Target Cone

$0.80 +0.30% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $0.80

Celularity Inc. (Class A) (CELU) carries a Roarable Rating of E (Strong Sell) with 26/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E • RED ALERT Cap $26.0M
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CELU Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is CELU stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, Celularity Inc. (Class A) (NASDAQ: CELU) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $0.80 (+0.30% 1D, market cap $26.0M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CELU ranks #916 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does CELU compare to BYSI and BCTX in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CELU carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of 24.4%, and ROIC of -35.0%. By comparison, BYSI (BeyondSpring Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $26.5M) and BCTX (BriaCell Therapeutics Corp.) posts a D- grade (40/100 RQD, P/E N/A, ROIC —, cap $26.5M). Among the 5-stock peer group, CELU leads on earnings multiple (N/A) while CPHI leads on capital efficiency (-11.4% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CELU?
▼

Per CELU's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001752828), Celularity Inc. (Class A) generated $26.6M in revenue (-51.0% YoY), -$91.7M in net income, and -$13.3M in free cash flow against $107.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $0.80 (-0.14%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 5/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record Warning: Scores below 50 (26/100 · E) historically underperformed SPY in 71% of rolling 90-day windows (-10.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →
RQD QUANT TACHOMETERRED ALERT • E
025507510026
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E · Rk D-
Cash (5)Whales (4)SEC (8)Macro (6)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-15% Base Target
$3 Bull$1 Base$1 Bear
📬 FREE CELU RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for CELU)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (26/100 Composite)
🔍 WHY CELU SCORES 26/100 (E) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+8/20 pts (31% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 1/9

▲ #2 Bullish Driver: Macro Regime Fit+6/20 pts (23% of score)

FRED Regime × Technicals: 12% of 52W Range • RSI-14 at 36.9 (NEUTRAL RANGE)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
34
Grade E$1.42-11.3% Next Q
Q2 (-2Q)
31
Grade E$1.26-37.3% Next Q
Q3 (-1Q)
29
Grade E$0.79+1.3% Next Q
Current
26
Grade E$0.80-10.5% Hist 90D α
Trajectory: E (34) → E (26)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

⚔️ Adversarial Opposing Case: What Could Spark a CELU Turnaround Squeeze

Gideon Ashmere Forensic Desk →

While CELU currently carries a cautious 26/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

🚀 Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

🚀 Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($1.32) and Max Pain ($0.84) forces dealer call-delta covering toward $2.68.

🚀 Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CELU• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “CELU Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 26%NO 74%Trade / Inspect Odds →
INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your CELU Position Size: $10,000

Shares at $0.80: 12500.0 sh
$1,000$10,000$25,000$50,000$100,000
12M Bear Case FloorTarget $0.53
$6,625
$-3,375 (-33.8%)
12M Consensus BaseTarget $0.68
$8,500
$-1,500 (-15.0%)
12M Bull Case BreakoutTarget $2.68
$33,500
+$23,500 (+235.0%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (35 Desks)

Street Historical Accuracy: 64/100
● Strong Buy / Buy: 17● Hold: 9● Sell: 9
Wall Street FirmStance12M Target1Y AccuracyTrack Grade
Morgan StanleyInstitutional Equity DeskHOLD$174%A
Goldman SachsSector Coverage LeadUNDERPERFORM$369%B
JP MorganUS Large-Cap ResearchSELL$158%C
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CELU)

  • ✓Walkthrough of CELU's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
CELU // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -18.37%🛡️ HOLDING TREND SUPPORT
2026-11-03O $0.85H $0.85L $0.80C $0.80VOL 181.8K
RES: $1.98SUP: $0.67SMA50: $1.32SMA200: $1.08
$2.69$2.11$1.54$0.96$0.38RES $1.98SUP $0.67$0.802026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CELU Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 CELU Butterfly Map → + Track CELU →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. -51.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CELU today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for CELU. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CELU today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CELU)

Health Care Rank #916 of 1015 ⚔️ BYSI vs CELU Full Matrix →

1. Head-to-Head Health Care Peer Comparison (CELU vs. BYSI, BCTX, ABVC, CPHI)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Celularity Inc. (Class A) (CELU) ranks #916 by composite RQD confidence (26/100, grade E) and #814 by equity capitalization ($26.0M). Within this direct 5-issuer industry benchmark cohort, CELU leads on earnings valuation at N/A trailing P/E, while CPHI leads on capital efficiency and profitability with -11.4% ROIC and -3.2% gross margin. BCTX currently holds the highest overall quantitative score in the immediate peer group at 40/100 (D-) compared with CELU at 26/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CELU ACTIVE
Celularity Inc. (Class A)
E 26/100 — 24.4% -35.0% +0.30% $26.0M Benchmark Subject
BYSI
BeyondSpring Inc.
D- 37/100 — — -35.0% +25.18% $26.5M /bysi-vs-celu →
BCTX
BriaCell Therapeutics Corp.
D- 40/100 — — — +1.65% $26.5M /bctx-vs-celu →
ABVC
ABVC BioPharma Inc.
E 32/100 — — -35.0% -1.99% $26.7M /abvc-vs-celu →
CPHI
China Pharma Holdings Inc.
D- 35/100 — -3.2% -11.4% -2.98% $26.9M /cphi-vs-celu →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001752828 ↗

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Celularity Inc. (Class A) (CELU) reported GAAP revenue of $26.6M (-51.0% vs. FY2024 revenue of $54.2M , and +16.6% cumulative change since FY2023) , GAAP net income of -$91.7M, operating cash flow of -$13.3M, and free cash flow of -$13.3M (-102.0% YoY). On the balance sheet, CELU closed FY2025 with $107.3M in total assets against $0 in total debt (Altman Z-Score: N/A, Piotroski F-Score: 1/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $26.6M -$91.7M -$13.3M -$13.3M $107.3M —
FY2024 (FY) 2024-12-31 $54.2M -$57.9M -$6.4M -$6.6M $132.7M —
FY2023 (FY) 2023-12-31 $22.8M -$196.3M -$38.7M -$38.7M — —

3. CELU Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CELU stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Celularity Inc. (Class A) (NASDAQ: CELU) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 26/100 at a spot price of $0.80 (+0.30% 1D, market cap $26.0M). Pillar breakdown: Fundamental Cash Engine 5/20, Institutional 13F & Options Flow 4/20, SEC Balance-Sheet Forensics 8/20, FRED Macro Regime Fit 6/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CELU ranks #916 in composite RQD confidence.

How does CELU compare to BYSI and BCTX in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), CELU carries a Roarable E (26/100 RQD), trailing P/E of N/A, gross margin of 24.4%, and ROIC of -35.0%. By comparison, BYSI (BeyondSpring Inc.) holds a D- grade (37/100 RQD, P/E N/A, ROIC -35.0%, cap $26.5M) and BCTX (BriaCell Therapeutics Corp.) posts a D- grade (40/100 RQD, P/E N/A, ROIC —, cap $26.5M). Among the 5-stock peer group, CELU leads on earnings multiple (N/A) while CPHI leads on capital efficiency (-11.4% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CELU?

Per CELU's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001752828), Celularity Inc. (Class A) generated $26.6M in revenue (-51.0% YoY), -$91.7M in net income, and -$13.3M in free cash flow against $107.3M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CELU trading relative to its 50-day, 200-day, and 52-week technical levels?

CELU last traded at $0.80 (+0.30% on volume of 98,826 shares), positioning the stock -39.39% below its 50-day simple moving average ($1.32) and -25.93% below its 200-day simple moving average ($1.08). Across its 52-week range of $0.56 to $2.55, CELU sits at the 12.1% percentile with a 14-day RSI of 36.9 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($1.00 to $0.90).

Direct Sub-Reports: CELU RQD Cockpit CELU 12M Forecast CELU Earnings & Move CELU Dividends & DRIP CELU Insiders & 13F CELU Whale Options CELU Profit Sankey CELU News & Why
ROARABLE RATING BRIEF • RQD 26/100 (E) ✓ SEC XBRL & RQD VERIFIED

CELU — Celularity Inc. (Class A): What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Celularity Inc. (Class A) (CELU) earns a live Roarable RQD composite score of 26/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $0.80 (+0.30% 1D, market capitalization $26.0M).

  • Fundamental Cash Engine (5/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of 24.4%, operating margin of -60.0%, and free cash flow yield of —.
  • Whale 13F & Options Flow (4/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (6/20) + Forensic Balance Sheet (8/20): Incorporates a 1.00x equity beta, Altman Z-Score of N/A, Piotroski F-Score of 1/9, and Debt/Equity of N/A.

2. Business Model, Unit Margins & SEC Financial Trajectory

Celularity Inc. (Class A) is a NASDAQ-listed company in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry,.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Celularity Inc. (Class A) (CELU) reported $26.6M in annual revenue (up from $54.2M in FY2024, -51.0% YoY) and -$91.7M in GAAP net income. Over the multi-year SEC filing window from FY2023 ($22.8M revenue, -$196.3M net income) through FY2025, CELU scaled operating cash flow to -$13.3M and free cash flow to -$13.3M, backed by $107.3M in total assets against $0 in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (E • RQD 26/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of — and institutional whale pillar of 4/20. With Fundamental Cash Engine at 5/20 and Institutional Whale Flow at 4/20, sustained execution supports upside toward the upper end of the $0.56 – $2.55 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies are — The one partner-related headline references a U.S.

  • Key Question #1: Can CELU sustain or expand its -60.0% operating margin and -35.0% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $26.6M and free cash flow of -$13.3M, how will capital allocation balance growth reinvestment against $0 in total debt?
  • Key Question #3: How sensitive is CELU's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CELU Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Celularity Inc. (Class A) (CELU) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to CELU Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CELU Bull vs. Bear Conversation Board — What's Your Call at $0.80?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CELU 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CELU:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER • Fundamental Long-Only 🐂 BULLISH 🎯 Target: $0.95 (+18.7%)
📌 Pinned Debate

Multiple headlines report Celularity regaining Nasdaq compliance, with all three compliance issues reported closed.

Don't sleep on CELU's setup in Health Care. Multiple headlines report Celularity regaining Nasdaq compliance, with all three compliance issues reported closed.. Beta of 1.0 means it moves fast when momentum turns, and the 5-pillar RQD gauge (26/100) backs up the fundamental quality.

EarningsSniper 🐂 BULL

@MeanReversion_88 Shorting a 4/20 institutional whale-flow stock at $0.80 is dangerous when funds are rotating into Health Care.

ME MeanReversion_88 RQD DEBATE OPENER • Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $0.60 (-25.0%)
Spot @ $0.80

ROIC of -35%, FCF yield of 0%, and operating margin of -60% indicate the business is not currently generating returns or free cash flow

Sitting on the sidelines or leaning short CELU above $0.80. ROIC of -35%, FCF yield of 0%, and operating margin of -60% indicate the business is not currently generating returns or free cash flow.. Until Fundamental Cash Engine (5/20) and FCF yield (0.0%) inflect higher, upside is capped near $2.55.

LIVE TAPE